The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
| Non-cash interest expense | - | 0 | 489 |
| Net loss | -10,619 | -6,908 | -38,441 |
| Stock-based compensation expense | 876 | 51 | 15,340 |
| Amortization of right of use-assets | 174 | 168 | 466 |
| Gain on early extinguishment of lease liability | - | 0 | 149 |
| Accretion of discounts on marketable securities, net | 7 | 38 | 33 |
| Loss on disposal of property and equipment | - | 0 | 0 |
| Non-cash interest expense | 0 | - | - |
| Non-cash research and development expenses for the common stock issuable pursuant to hutchmed agreement | - | 0 | 0 |
| Depreciation and amortization expense | 0 | 393 | 6 |
| Prepaid expenses and other current assets | -141 | 383 | 3,574 |
| Other non-current assets | - | -72 | 1,277 |
| Deposits and other non-current assets | 3,452 | - | - |
| Accounts payable | -871 | -641 | -2,179 |
| Accrued expenses and other current liabilities | -494 | 848 | -9,945 |
| Deferred revenue | 0 | 0 | -650 |
| Other non-current liabilities | 11 | -236 | 15 |
| Operating lease liabilities | -559 | -544 | -694 |
| Net cash used in operating activities | -14,800 | -7,218 | -40,626 |
| Cash divested in non-ox40 divestiture | - | 0 | 5,215 |
| Proceeds from disposal of property and equipment | - | 0 | 0 |
| Purchases of marketable securities | 10,937 | 8,913 | 1,485 |
| Maturities of marketable securities | 10,497 | 7,549 | 2,250 |
| Net cash used in investing activities | -440 | -1,364 | -4,450 |
| Proceeds from term loan | - | 0 | 15,000 |
| Proceeds from exercise of stock options | 35 | 0 | 45 |
| Issuance costs in connection with reverse recapitalization | - | 0 | -5,338 |
| Cash acquired in connection with reverse recapitalization | - | 0 | -54,631 |
| Payment of issuance costs in connection with reverse recapitalization | 3,279 | - | - |
| Proceeds from common stock issued in pipe financing, net of issuance costs | - | 0 | 71,130 |
| Payment of deferred offering costs | 0 | - | - |
| Net cash provided by (used in) financing activities | -3,244 | 0 | 135,468 |
| Effect of exchange rate changes on cash and cash equivalents | 0 | -48 | 652 |
| Net change in cash and cash equivalents | -18,484 | -8,630 | 91,044 |
| Cash and cash equivalents at beginning of period | 94,532 | 103,162 | 12,118 |
| Cash and cash equivalents at end of period | 76,048 | 94,532 | 103,162 |
ImageneBio, Inc. (IMA)
ImageneBio, Inc. (IMA)